symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
GERN,1.85,0.803664,5531185,968236365,0,1.73-3.84,-0.05,Geron Corporation,USD,0000886744,US3741631036,374163103,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.geron.com,"Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.",Dr. John A. Scarlett M.D.,Healthcare,US,107,650 473 7700,919 East Hillsdale Boulevard,Foster City,CA,94404,1.08357,2.25643,https://financialmodelingprep.com/image-stock/GERN.png,1996-07-31,False,False,True,False,False
